CClinicalTrials.gg
CompletedNCT03115879Updated Apr 14, 2017

The Effect High Velocity Low Amplitude Hip Mobilization on Strength in Subjects With Lower Extremity Pathology

An interventional study of Hip mobilization and Hip manipulation simulation in Hip Joint and Muscle Weakness, sponsored by Faculdade de Ciências Médicas da Santa Casa de São Paulo. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-14.

Sponsored by Faculdade de Ciências Médicas da Santa Casa de São Paulo · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Feb 2015, registered Mar 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Introduction: Lower extremity weakness associated with musculoskeletal pathology can cause activity limitations. Physical therapy intervention in the form of exercise is commonly directed at improving muscular performance, however, neuromuscular adaptations may limit the effectiveness of traditional strengthening exercises. Manual therapy techniques have been used as a disinhibitory intervention to increase muscle activation and strength before participating in strengthening exercises or performing functional tasks While there is recent evidence to support joint mobilization as a valuable manual therapy disinhibitory intervention Currently, there is no evidence to substantiate anecdotal experience that a HVLAT hip distraction mobilization improves muscle performance in subjects with lower extremity pathology and lower extremity weakness. The purpose of this study was to determine if a HVLAT hip distraction mobilization would result in an immediate change of maximal force output of the quadriceps, gluteus maximus and gluteus medius.

Methods: Forty individuals with a lower extremity pathology volunteered for this study. Inclusion criteria were having a unilateral musculoskeletal pathology, being greater than 18 years of age, 10% decrease in muscle strength in symptomatic side compared to healthy side, and absence of medical precautions that would prevent a maximal effort strength test and exclusion criteria included individuals with a history lower extremity recent muscle or tendon ruptures (within the past 6 months) and postoperative knee, hip and ankle surgery. Demographic data, including diagnosis from referring physician were collected. All subjects completed the Lower extremity function scale (LEFS). A single evaluator blinded to the involved extremity was responsible for quadriceps, gluteus medius and maximus strength analysis pre and post mobilization of both symptomatic and non-symptomatic sides. The subject underwent the HVLAT hip distraction mobilization of the symptomatic side, and an immediate re-assessment of strength of both symptomatic and non-symptomatic sides followed the mobilization.

02

Conditions studied

  • Hip Joint
  • Muscle Weakness

Browse trials for

03

In context

Muscle Weakness

601 studies on the registry are indexed under Muscle Weakness; 99 are open to participants now.

This study's enrollment of 40 is below the median of 46 across 444 interventional studies indexed under Muscle Weakness.

Browse Muscle Weakness studies →

Lead sponsor

Faculdade de Ciências Médicas da Santa Casa de São Paulo is the lead sponsor of 39 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Individuals with a lower extremity pathology volunteered for this study
  • Being greater than 18 years of age
  • 10% decrease in muscle strength in symptomatic side compared to healthy side
  • Absence of medical precautions that would prevent a maximal effort strength test.

Exclusion criteria

Exclusion Criteria:

  • Included individuals with a history lower extremity arthroplasty.
  • Recent muscle or tendon ruptures (within the past 6 months)
  • Unhealed fractures
  • Neurological diseases
  • Malignant cancer
  • Osteoporosis
  • Active infections processes
  • Early postoperative knee, hip and ankle surgery with range of motion and weight bearing restrictions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    Placebo Group

    Hip manipulation simulation

    Other: Hip manipulation simulation

  • Experimental
    Manipulation Group

    Hip manipulation

    Other: Hip mobilization

Interventions

  • OtherHip mobilization

    High velocity low amplitude hip mobilization of the experimental group

  • OtherHip manipulation simulation

    Hip manipulation simulation

06

What researchers measure

Primary outcomes

  1. Muscle strength

    A Lafayette dynamometer was used to evaluate the maximum isometric torque of the muscles

    Time frame: Assessment of muscle strength was performed after 10 minutes of manipulation

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03115879
Lead sponsor
Faculdade de Ciências Médicas da Santa Casa de São Paulo
Responsible party
Diego Galace de Freitas (Principal Investigator, Faculdade de Ciências Médicas da Santa Casa de São Paulo) — Principal investigator
First posted
Apr 14, 2017
Start date
Feb 2015
Primary completion
Mar 2016
Completion
Oct 2016
Last update
Apr 14, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion